[Pubmed] Azathioprine Toxicity in Patients With Myasthenia Gravis: A Single Center Experience

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6507
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Windows 10 Chrome

[Pubmed] Azathioprine Toxicity in Patients With Myasthenia Gravis: A Single Center Experience

Message par RSS-Bot »


Muscle Nerve. 2026 Jan 28. doi: 10.1002/mus.70165. Online ahead of print.

ABSTRACT

INTRODUCTION/AIMS: Azathioprine (AZA) is a first-line immunosuppressive agent for myasthenia gravis (MG), yet most toxicity data for AZA are from gastrointestinal literature. The aim of the current study is to add a large MG patient cohort with a comprehensive evaluation of the adverse event profile of AZA and associations between patient demographics and drug reactions.

METHODS: Patients were identified from the Duke Electronic Medical Record using EPIC's SlicerDicer tool.

INCLUSION CRITERIA: MG diagnosis confirmed by antibody/electrodiagnostic testing, evaluation by a Duke neuromuscular physician, and AZA use between January 1, 2014 and January 7, 2023. Drug reaction was defined as an abnormal lab result or symptomatic side effect after AZA initiation.

RESULTS: Among 145 patients, 96 (66%) developed a drug reaction; 63 (43.5%) required AZA dose reduction or discontinuation, and 23 (16%) had symptomatic side effects. Most reactions improved with dose reduction or observation. Leukopenia, macrocytosis, and hepatotoxicity were the most frequent. For every additional comorbidity, the odds of drug reaction increased by 30% (OR 1.3; 95% CI 1.12-1.51; p < 0.001). Flu-like reactions occurred in 10% of patients. Cancer incidence (4.1%) was rare and there were no cases of Pneumocystis jirovecii pneumonia despite rare use of trimethoprim-sulfamethoxazole prophylaxis.

DISCUSSION: AZA drug reactions were common but infrequently severe or symptomatic. Higher comorbidity burden predicted drug reactions. Most laboratory abnormalities resolved without AZA discontinuation, supporting individualized monitoring and dose adjustment rather than automatic cessation. Lower doses should be considered for balancing efficacy with dose-dependent drug reactions.

PMID:41603484 | DOI:10.1002/mus.70165


Source: https://pubmed.ncbi.nlm.nih.gov/4160348 ... 22+67771e2
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »